Literature DB >> 26198404

Detection of prostate cancer index lesions with multiparametric magnetic resonance imaging (mp-MRI) using whole-mount histological sections as the reference standard.

Filippo Russo1, Daniele Regge1, Enrico Armando1, Valentina Giannini1, Anna Vignati1, Simone Mazzetti1, Matteo Manfredi2, Enrico Bollito3, Loredana Correale4, Francesco Porpiglia2.   

Abstract

OBJECTIVE: To evaluate the sensitivity of multiparametric magnetic resonance imaging (mp-MRI) for detecting prostate cancer foci, including the largest (index) lesions. PATIENTS AND METHODS: In all, 115 patients with biopsy confirmed prostate cancer underwent mp-MRI before radical prostatectomy. A single expert radiologist recorded all prostate cancer foci including the index lesion 'blinded' to the pathologist's biopsy report. Stained whole-mount histological sections were used as the reference standard. All lesions were contoured by an experienced uropathologist who assessed their volume and pathological Gleason score. All lesions with a volume of >0.5 mL and/or pathological Gleason score of >6 were defined as clinically significant prostate cancer. Multivariate analysis was used to ascertain the characteristics of lesions identified by MRI.
RESULTS: In all, 104 of 115 index lesions were correctly diagnosed by mp-MRI (sensitivity 90.4%; 95% confidence interval [CI] 83.5-95.1%), including 98/105 clinically significant index lesions (93.3%; 95% CI 86.8-97.3%), among which three of three lesions had a volume of <0.5 mL and Gleason score of >6. Overall, mp-MRI detected 131/206 lesions including 13 of 68 'insignificant' prostate cancers. The multivariate logistic regression modelling showed that pathological Gleason score (odds ratio [OR] 11.7, 95% CI 2.3-59.8; P = 0.003) and lesion volume (OR 4.24, 95% CI 1.3-14.7; P = 0.022) were independently associated with the detection of index lesions at MRI.
CONCLUSIONS: This study shows that mp-MRI has a high sensitivity for detecting clinically significant prostate cancer index lesions, while having disappointing results for the detection of small-volume, low Gleason score prostate cancer foci. Thus, mp-MRI could be used to stratify patients according to risk, allowing better treatment selection.
© 2015 The Authors BJU International © 2015 BJU International Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  diagnostic imaging; magnetic resonance imaging; prostatic neoplasm

Mesh:

Year:  2015        PMID: 26198404     DOI: 10.1111/bju.13234

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  14 in total

Review 1.  Multiparametric magnetic resonance imaging: Overview of the technique, clinical applications in prostate biopsy and future directions.

Authors:  Hüseyin Cihan Demirel; John Warren Davis
Journal:  Turk J Urol       Date:  2018-03-01

2.  A multicentric study on accurate grading of prostate cancer with systematic and MRI/US fusion targeted biopsies: comparison with final histopathology after radical prostatectomy.

Authors:  R Diamand; M Oderda; W Al Hajj Obeid; S Albisinni; R Van Velthoven; G Fasolis; G Simone; M Ferriero; J-B Roche; T Piechaud; A Pastore; A Carbone; G Fiard; J-L Descotes; G Marra; P Gontero; E Altobelli; R Papalia; P Kumar; D Eldred-Evans; A Giacobbe; G Muto; V Lacetera; V Beatrici; T Roumeguere; A Peltier
Journal:  World J Urol       Date:  2019-01-16       Impact factor: 4.226

3.  Pathologic correlation of transperineal in-bore 3-Tesla magnetic resonance imaging-guided prostate biopsy samples with radical prostatectomy specimen.

Authors:  Erik Velez; Andriy Fedorov; Kemal Tuncali; Olutayo Olubiyi; Christopher B Allard; Adam S Kibel; Clare M Tempany
Journal:  Abdom Radiol (NY)       Date:  2017-08

4.  Multiparametric magnetic resonance imaging of the prostate with computer-aided detection: experienced observer performance study.

Authors:  Valentina Giannini; Simone Mazzetti; Enrico Armando; Silvia Carabalona; Filippo Russo; Alessandro Giacobbe; Giovanni Muto; Daniele Regge
Journal:  Eur Radiol       Date:  2017-04-06       Impact factor: 5.315

5.  Multiparametric magnetic resonance imaging for prostate cancer-a comparative study including radical prostatectomy specimens.

Authors:  Liam Toner; Nathan Papa; Marlon Perera; Nikolas Katelaris; Mahesha Weerakoon; Kwang Chin; Laurence Harewood; Damien M Bolton; Nathan Lawrentschuk
Journal:  World J Urol       Date:  2016-10-26       Impact factor: 4.226

6.  The impact of 3D models on positive surgical margins after robot-assisted radical prostatectomy.

Authors:  Cristian Fiori; Francesco Porpiglia; Enrico Checcucci; Angela Pecoraro; Daniele Amparore; Sabrina De Cillis; Stefano Granato; Gabriele Volpi; Michele Sica; Paolo Verri; Alberto Piana; Pietro Piazzolla; Matteo Manfredi; Enrico Vezzetti; Michele Di Dio
Journal:  World J Urol       Date:  2022-07-05       Impact factor: 3.661

Review 7.  Active surveillance for prostate cancer: current evidence and contemporary state of practice.

Authors:  Jeffrey J Tosoian; H Ballentine Carter; Abbey Lepor; Stacy Loeb
Journal:  Nat Rev Urol       Date:  2016-03-08       Impact factor: 14.432

8.  What Are We Missing? False-Negative Cancers at Multiparametric MR Imaging of the Prostate.

Authors:  Samuel Borofsky; Arvin K George; Sonia Gaur; Marcelino Bernardo; Matthew D Greer; Francesca V Mertan; Myles Taffel; Vanesa Moreno; Maria J Merino; Bradford J Wood; Peter A Pinto; Peter L Choyke; Baris Turkbey
Journal:  Radiology       Date:  2017-10-20       Impact factor: 11.105

9.  Should Grade Group 1 (GG1) be called cancer?

Authors:  Craig V Labbate; Gladell P Paner; Scott E Eggener
Journal:  World J Urol       Date:  2021-01-11       Impact factor: 4.226

10.  Computer-Aided Diagnosis Improves the Detection of Clinically Significant Prostate Cancer on Multiparametric-MRI: A Multi-Observer Performance Study Involving Inexperienced Readers.

Authors:  Valentina Giannini; Simone Mazzetti; Giovanni Cappello; Valeria Maria Doronzio; Lorenzo Vassallo; Filippo Russo; Alessandro Giacobbe; Giovanni Muto; Daniele Regge
Journal:  Diagnostics (Basel)       Date:  2021-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.